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This research is an extension of our studies on pyrimidine and pyrimidinethione de-
rivatives as synthons to prepare fused heterocyclic compounds (1, 2). Some of the py-
rimidine and fused heterocyclic pyrimidine derivatives have proved to be active antivi-
ral, antitumor, analgesic and antimicrobial agents (3–6). In addition, pyrimidothiazine,
thiazolopyrimidine and oxazolidinone derivatives are of great antimicrobial activity (7).
Recently, we have found that certain substituted pyrimidines and their heterocyclic de-
rivatives show antimicrobial and antiinflammatory (8, 9) as well as antitumor activities
(10, 11). On the other hand, thioxopyrimidine and thiazolopyrimidine derivatives have
anticancer activities (12, 13). In view of these observations and in continuation of our
previous work in heterocyclic chemistry, we have synthesized some new pyrimidine and
thiazolopyrimidine derivatives and tested their antimicrobial activity.
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3-Amino-5-(4-chlorophenylamino)-4-cyanofuran-2-carbox-
amide (2) was used as the key molecule for preparation
of various furopyrimidines 3-9 and formation of spiro-cy-
cloalkane furopyrimidines 10, 11. Also, poly fused hete-
rocyclic compounds 13-17 were prepared from compound
2. The synthesized compounds were screened for their
antimicrobial activity.
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EXPERIMENTAL
All melting points are uncorrected and were measured using an Electro-thermal IA
9100 apparatus (Shimadzu, Japan). IR spectra were recorded as potassium bromide pel-
lets on a Perkin-Elmer 1650 spectrophotometer (Perkin-Elmer, USA). 1H NMR was recor-
ded on a Jeol-Ex-270 NMR spectrometer (Jeol, Japan) and chemical shifts were expressed
as part per million (ppm d values) against TMS as the internal reference standard. Mass
spectra were recorded on a VG 2AM-3F mass spectrometer (Thermo Electron, USA). Mi-
croanalyses were operated using a Yanaco CHN Corder Elemental Analyzer (Japan) and
the results were within the accepted range (± 0.2 %) of calculated values. Follow-up of
the reactions and purity checking of the compounds were done by TLC on silica gel-
-coated aluminum sheets (Type 60 F254, Merck, Germany).
Syntheses
2-[3-(4-Chlorophenyl)-4-oxooxazolidin-2-ylidene]malononitrile (1). – To a stirred mixture
of malononitrile (0.66 g, 0.01 mol), p-chlorophenylisocyanate (1.53 g, 0.01 mol) in distilled
water (20 mL) containing KOH (1 g) at room temperature, ethyl chloroacetate (1.22 g,
0.01 mol) in ethanol (25 mL) was added after 1h. The reaction mixture was heated under
reflux for 2 h, the obtained solid was collected by filtration and crystallized from metha-
nol to give compound 1 as white crystals.
3-Amino-5-(4-chlorophenylamino)-4-cyanofuran-2-carboxamide (2). – A solution of com-
pound 1 (2.56 g, 0.01 mol) in ammonia solution (25 %, 30 mL) was stirred at room tem-
perature for 6 h. The solid formed was filtered off, dried and crystallized from chloro-
form to give compound 2 as a brown powder.
6-(4-Chlorophenylamino)-4-oxo-3,4-dihydrofuro[3,2-d]pyrimidin-7-carboxamide (3). – A mix-
ture of compound 2 (2.77 g, 0.01 mol) and formic acid (20 mL) was refluxed for 6 h. The
reaction mixture was concentrated under reduced pressure, the obtained precipitate was
collected by filtration, dried and crystallized from dioxane to give compound 3 as yel-
low crystals.
6-(4-Chlorophenylamino)-4-oxo-3-phenyl-2-thioxo-1,2,3,4-tetrahydro-furo[3,2-d]pyrimi-
dine-7-carbonitrile (4). – A mixture of compound 2 (2.77 g, 0.01 mol) and phenylisothio-
cyanate (1.35 g, 0.01 mol) in glacial acetic acid (25 mL) was refluxed for 6 h. The reaction
mixture was allowed to cool; the formed solid was filtered off, dried and crystallized
from ethyl acetate to give 4 as a light brown powder.
6-(4-Chlorophenylamino)-2,4-dioxo-1,2,3,4-tetrahydro-furo[3,2-d]pyrimidine-7-carbonitri-
le (5). – A mixture of compound 2 (2.77 g, 0.01 mol) and ethylchloroformate (1.08 g, 0.01
mol) in acetic acid (15 mL) was refluxed for 10 h. The reaction mixture was allowed to
cool, the solid product was filtered off and crystallized from DMSO to give the corre-
sponding compound 5 as a brown powder.
1-(3-Chloro-2-oxopropyl)-6-(4-chlorophenylamino)-4-oxo-3-phenyl-2-thioxo-1,2,3,4-tetrahy-
dro-furo[3,2-d]pyrimidine-7-carbonitrile (6) and 6-(4-chlorophenylamino)-1-(oxiran-2-yl-me-
thyl)-4-oxo-3-phenyl-2-thioxo-1,2,3,4-tetrahydro-furo[3,2-d]pyrimidine-7-carbonitrile (7). – A
mixture of compound 4 (3.95 g, 0.01 mol) and sodium hydride (0.24 g, 0.01 mol) in dry
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dioxane (20 mL) was stirred at 60 oC for 3 h. The reaction mixture was cooled at room
temperature, then dichloroacetone or epichlorohydrine (0.01 mol) was added under stir-
ring. Stirring was continued for 5 h at room temperature. The reaction mixture was eva-
porated under reduced pressure; the residue was washed with distilled water, filtered
off and crystallized from methanol to give compound 6 or 7.
6-(4-Chlorophenylamino)-4-oxo-3-phenyl-2-(2’,3’,4’,6’-tetra-O-acetyl-1’-thio-b-D-gluco-
pyranosyl)-1,2,3,4-tetrahydrofuro[3,2-d]pyrimidine-7-carbonitrile (8). – To a solution of 2 (2.77
g, 0.01 mol) in aqueous potassium hydroxide (0.56 g, 0.01 mol) in distilled water (5 mL),
a solution of 2,3,4,6-tetra-O-acetyl-a-D-glucopyranosyl bromide (4.11 g, 0.011 mol) in ac-
etone (30 mL) was added. The reaction mixture was stirred at room temperature for 14 h
(under TLC control). The solvent was evaporated under reduced pressure at 40 oC and
the crude product was filtered off and washed with distilled water to remove KBr for-
med. The product was dried, and crystallized from diethyl ether as a brown powder.
6-(4-Chlorophenylamino)-4-oxo-2-phenyl-1,2,3,4-tetrahydrofuro[3,2-d]pyrimidine-7-carboni-
trile (9). – A mixture of compound 2 (2.77 g, 0.01 mol) and benzaldehyde (1.06 g, 0.01
mol) in glacial acetic acid (20 mL) was refluxed for 4 h. The reaction mixture was evapo-
rated under reduced pressure and the obtained residue was triturated with diethyl ether.
The formed solid was collected by filtration, dried and crystallized from dioxane to give
compound 9 as yellow crystals.
6-(4-Chlorophenylamino)-7-cyano-1,3,4-trihydrospirocyclopentane(1’,2)-furo[3,2-d]pyrimidin-
4-one (10) and 6-(4-chlorophenylamino)-7-cyano-1,3,4-trihydrospirocyclohexane(1,2)furo[3,2-
-d]pyrimidin-4-one (11). – A mixture of compound 2 (2.77 g, 0.01 mol), cyclopentanone or
cyclohexanone (0.01 mol) and sodium acetate (2 g) in glacial acetic acid (20 mL) was re-
fluxed for 6 h. The reaction mixture was cooled, then poured into ice-water. The precipi-
tated solid was filtered off, washed with water, dried and crystallized from ethanol to
give compound 10 or 11.
6-(4-Chlorophenyl)-6-(7-cyano-2-methyl-4-oxo-4H-furo[3,2-d][1,3]oxazin-6-yl)acetamide (12).
– A solution of compound 2 (2.77 g, 0.01 mol) in acetic anhydride (20 mL) was refluxed
for 8 h. The reaction mixture was concentrated under reduced pressure. The precipitated
solid was collected by filtration, dried and crystallized from ethanol to give compound
12 as orange crystals.
1-(4-Chlorophenyl)-4-imino-2,6-dithioxo-1,4,6,7-tetrahydropyrimido[5,4-b]furo[5,4-d]-1,3-
thiazin-8-one (13). – A mixture of compound 2 (2.77 g, 0.01 mol), carbon disulfide (1.56 g,
0.02 mol) and dry pyridine (20 mL) was refluxed for 20 h. The reaction mixture was co-
oled then poured into ice-water. The precipitated solid was filtered off, washed with wa-
ter, dried and crystallized from DMF.
1-(4-Chlorophenyl)-2,3-dithioxo-8-oxo-2,2’,10,11-tetrahydrothiazolo[1,3-b]pyrimido[1,3-el]-
furo-[5,4-e]pyrimidine (14) and 1-(4-chlorophenyl)-2,3-dithioxo-8-oxo-2,2’,3,3’,11,12-hexahy-
dro-thiazino[1,3-b]-pyrimido[1,3-e]furo[5,4-e]pyrimidine (15). – A mixture of compound 13 (3.95
g, 0.01 mol), chloroacetic acid or chloropropionic acid (0.01 mol) and anhydrous sodium
acetate (2 g) was refluxed in glacial acetic acid/acetic anhydride (40 mL, 3:1) for 3 h. The
reaction mixture was cooled and poured into water; the obtained precipitate was filtered
off and crystallized from methanol to give compound 14 or 15.
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7-[Phenylmethylene]-1-(4-chlorophenyl)-2,3-dithioxo-8-oxo-2,2’,10,11-tetrahydrothiazolo[1,3-
-b]-pyrimido[1,3-e]furo-[5,4-e]pyrimidine (16) and 8-[phenylmethylene]-1-(4-chlorophenyl)-
-2,3-dithioxo-8-oxo-2,2’,3,3’,11,12-hexahydrothiazino[1,3-b]-pyrimido[1,3-e]furo[5,4-e]pyrimidine
(17). – A mixture of compound 14 or 15 (0.01 mol), benzaldehyde (1.06 g, 0.01 mol) and
anhydrous sodium acetate (2 g) in glacial acetic acid/acetic anhydride (40 mL, 3:1) was
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refluxed for 3 h. The reaction mixture was allowed to cool and poured into water. The
solid substance was filtered off and crystallized from acetic acid/water to give aryl
methylene derivative 16 or 17.
Physico-chemical and spectral data of the synthesized compounds are given in Ta-
bles I and II.
Antimicrobial activity
The antibacterial activity of synthesized compounds was tested against Escherichia
coli NRRL B-210 (Gram-negative bacterium), Bacillus subtilis NRRL B-543 and Staphylo-
coccus aureus NRRL B-313 (Gram-positive bacteria) using a nutrient agar medium. The
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4.9 (s, 2H, oxazolidine), 7.15 (d, 2H, J = 5.8
Hz, Ar-H), 7.62 (d, 2H, J = 5.9 Hz, Ar-H)
259 [M+] (100), 261
[M++2] (31), 224(14),






6.50 (s, 2H, NH2, D2O exchangeable), 7.2 (d,
2H, J = 5.8 Hz, Ar-H), 7.6 (d, 2H, J = 5.8 Hz,
Ar-H), 7.8 (s, 2H, NH2 amide, D2O exchange-
able), 8.0 (s, 1H, NH, D2O exchangeable)
276 [M+] (80), 278
[M++2] (26), 241 (5),
232 (52), 165 (10), 150





6.5 (d, 2H, J = 5.3 Hz, Ar-H), 7.0 (d, 2H,
J = 5.4 Hz, Ar-H), 7.57 (br, 2H, NH2, D2O
exhangeable), 7.91 (s, 1H, pyrimidine
proton), 8.1, 10.8 (2s, 2H, 2NH, D2O
exchangeable)
304 [M+] (70), 306
[M++2] (20) 260 (19),






6.40 (d, 2H, J = 5.8 Hz, Ar-H), 6.8 (m, 2H,
Ar-H), 7.45 (m, 3H, Ar-H) 7.7 (d, 2H,
J = 5.7 Hz, Ar-H), 8.0, 10.6 (2s, 2H, 2NH,
D2O exchangeable)
394 [M+] (60), 396
[M++2] (20), 283 (23),






6.63 (d, 2H, J = 5.5 Hz, Ar-H), 7.2 (d, 2H,
J = 5.5 Hz, Ar-H), 7.8, 10.3, 11.0 (3s, 3H,
3NH, exchangeable)
302 [M+] (49), 304
[M++2] (14), 191 (10),






4.50 (s, 2H, CH2), 4.63 (s, 2H, CH2), 6.5
(d, 2H, J = 5.8 Hz, Ar-H), 6.75 (m, 2H, Ar-H),
7.21 (m, 3H, Ar-H), 7.6 (d, 2H, J = 5.8 Hz,
Ar-H), 7.9 (s, 1H, NH, D2O exchangeable)
484 [M+] (90), 486
[M++2] (27), 393 (30),
358 (55), 373 (9), 358





2.50 (m, 2H, CH2-oxirnyl ring), 2.80 (m, 1H,
CH-oxirnyl ring), 3.58 (d, 2H, J = 3.7 Hz,
CH2), 6.4 (d, 2H, J = 5.7 Hz, Ar-H), 6.64
(m, 2H, Ar-H), 7.01 (m, 3H, Ar-H), 7.7
(d, 2H, J = 5.6 Hz, Ar-H), 7.91 (s, 1H, NH,
D2O exchangeable)
450 [M+] (27), 439
(45), 424 (10), 393 (9),
226 (25), 211 (24)
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2.04–2.20 (4s, 12H, 4COCH3), 3.75 (m, 2H,
H-6’, H-6’’), 3.81 (m, 1H, H-5’), 3.98 (m, 2H,
H-4’, H-3’), 5.49 (m, 1H, H-2’), 5.70 (d, 1H,
J1'-2' = 9.8 Hz, H-1’), 6.58 (d, 2H, J = 5.8 Hz,
Ar-H), 6.71 (m, 2H, Ar-H), 6.98 (m, 3H, Ar-H),
7.65 (d, 2H, J = 5.9 Hz, Ar-H), 8.1 (s, 1H, NH,
D2O exchangeable)
725 [M+] (68), 727
[M++2] (18) 598 (23),
393 (14), 331 (5), 163





5.79 (s, 1H, pyrimidine proton), 6.59 (d, 2H,
J = 5.6 Hz, Ar-H), 6.84 (m, 2H, Ar-H), 7.10
(m, 3H, Ar-H), 7.45(d, 2H, J = 5.5 Hz, Ar-H),
7.9, 9.2, 10.3 (3s, 3H, 3NH, D2O exchangeable)
364 [M+] (38), 366
[M++2] (9) 287 (25),






1.50–1.96 (m, 8H, aliphatic), 6.89 (d, 2H,
J = 5.9 Hz, Ar-H), 7.2 (d, 2H, J = 5.9 Hz,
Ar-H), 7.93, 9.3, 10.4 (3s, 3H, 3NH, pyrimi-
dine, D2O exchangeable)
342 [M+] (20) 344
[M++2] (7), 286 (10),






1.30–1.74 (m, 10H, aliphatic), 6.66 (d, 2H,
J = 5.4 Hz, Ar-H), 7.31 (d, 2H, J = 5.5 Hz,
Ar-H), 8.1, 9.6, 10.1 (3s, 3H, 3NH,
pyrimidine, D2O exchangeable)
356 [M+] (38), 358
[M++2] (12), 286 (45),





1.30 (s, 3H, CH3), 2.4 (s, 3H, OCH3), 6.6
(d, 2H, J = 5.8 Hz, Ar-H), 7.3 (d, 2H,
J = 5.8 Hz, Ar-H)
343 [M+] (65), 345
[M++2] (22), 328 (58),







6.54 (d, 2H, J = 5.6 Hz, Ar-H), 7.23 (d, 2H,
J = 5.7 Hz, Ar-H), 9.3, 10.7, 11.2 (3s, 3H,
3NH, D2O exchangeable)
394 [M+] (30), 396
[M++2] (9), 378 (10),






3.30 (s, 2H, CH2), 6.48 (d, 2H, J = 5.9 Hz,
Ar-H), 7.14 (d, 2H, J = 5.9 Hz, Ar-H), 10.7
(s, 1H, NH, D2O exchangeable)
434 [M+] (30), 436
[M++2] (12), 322 (64),






2.9 (t, 2H, J = 3.3 Hz, CH2), 3.12 (t, 2H,
J = 4.2 Hz, CH2), 6.78 (d, 2H, J = 5.9 Hz,
Ar-H), 7.07 (d, 2H, J = 5.9 Hz, Ar-H),
10.8 (s, 1H, NH, D2O exchangeable)
448 [M+] (21), 450
[M++2] (8), 336 (12),






6.48 (d, 2H, J = 5.6 Hz, Ar-H), 6.90 (m,
2H, Ar-H), 7.07 (m, 3H, Ar-H), 7.42 (d, 2H,
J = 5.7 Hz, Ar-H), 7.98 (s, 1H, methylene
proton), 10.5 (s, 1H, NH, D2O exchangeable).
523 [M+] (49), 524
[M++2] (18), 431 (54),






3.20 (s, 2H, CH2), 6.57 (d, 2H, J = 5.9 Hz,
Ar-H), 6.90 (m, 2H, Ar-H), 7.07 (m, 3H,
Ar-H), 7.42 (d, 2H, J = 5.9 Hz, Ar-H), 8.3
(s, 1H, methylene proton), 10.45 (s, 1H,
NH, D2O exchangeable)
537 [M+] (47), 538
[M++2] (15), 445 (64),
424 (25), 268 (14), 111
(21)
a The solvent for compounds 1, 2, 3, 5, 7, 9, 14 is CDCl3 and for compounds 4, 6, 10, 11, 12, 13, 15, 16, 17, 18
is DMSO-d6.
antifungal activity of the compounds was tested against Candida albicans NRRL Y-477 us-
ing the Sabouraud dextrose agar medium.
Agar diffusion medium. – Nine compounds were screened in vitro for their antimi-
crobial activity by the agar diffusion method (14). A suspension of organisms was added
to a sterile nutrient agar medium at 45 °C and the mixture was transferred to a sterile
Petri dish and allowed to solidify. Holes of 10 mm in diameter were made using a cork
borer and filled with the solution of synthesized compounds (100 mg mL–1). A hole filled
with DMSO was used as control. The plates were left for 1 hour at room temperature as
a period of pre-incubation. The plates were then incubated at 37 °C for 24 hours and ob-
served for antibacterial activity. Diameters of the zone of inhibition were measured and
compared with that of the standard. Ciprofloxacin (50 mg mL–1) and ketoconazole (50 mg
mL–1) were used as standards for antibacterial and antifungal activity, respectively. The
observed zones of inhibition are presented in Table III.
Minimum inhibitory concentration. – Minimum inhibitory concentration (MIC) of the
test compounds was determined by the agar streak dilution method. Stock solutions of
synthesized compounds were made using DMSO as a solvent (68 mg mL–1). From this
stock solution, a series of concentrations was prepared (0.17, 0.34, 0.68, 0.85 and 1.7 mg
mL–1) and mixed with known quantities of molten sterile agar medium aseptically.
About 20 mL of the medium containing the tested compound was dispensed into a sterile
Petri dish. Then, the medium was allowed to solidify. Microorganisms were then strea-
ked one by one on the agar plates aseptically. After streaking, all the plates were incu-
bated at 37 °C for 24–48 h for antibacterial and antifungal activity, respectively. The lowest
concentration of the synthesized compound that inhibits the growth of the given bacte-
rium/fungus was considered as the minimum inhibitory concentration (MIC) of the test
compounds. The MIC values are tabulated in Table IV.
RESULTS AND DISCUSSION
Chemistry
4-Oxo-oxazolidin-2-ylidene malononitrile derivative 1 was prepared via condensa-
tion of malononitrile with p-chlorophenylisocyanate in alkaline medium, followed by ad-
dition of ethyl chloroacetate. Ammoniation of compound 1 afforded 3-amino-5-(4-chlo-
rophenylamino)-4-cyanofuran-2-carboxamide (2) according to the mechanism given in
Scheme 1. Compound 2 was used to synthesize some fused heterocyclic derivatives. Thus,
heating of compound 2 with an aliphatic acid, namely formic acid, resulted in the forma-
tion of 3,4-dihydrofuro[3,2-d]pyrimidine 3. Also, when reacted with phenylisothiocya-
nate in refluxing acetic acid it afforded the corresponding 1,2,3,4-tetrahydrofuro[3,2-d]
pyrimidine-7-carbonitrile 4 (Scheme 2). All the synthesized compounds were character-
ized by their physical, chemical and spectral data (Tables I and II). IR spectra of com-
pound 3 showed the presence of absorption bands at 1682 and 1702 cm–1 (2 C=O) and
the absence of a characteristic band (CN) due to hydrolysis of the cyano group; the MS
gave the molecular ion peak at m/z (%) = 394 (60).
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Furthermore, 4-cyanofuran-2-carboxamide 2 reacted with ethylchloroformate in re-
fluxing acetic acid to yield 2,4-dioxofuro[3,2-d]pyrimidine-7-carbonitrile 5. Beside cor-
rect values of elemental analyses, the spectral data for 5 are in agreement with the as-
signed structure (Scheme 2).
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In addition, alkylation of compound 4 with dichloroacetone or epichlorohydrine in
the presence of sodium hydride afforded the corresponding N-alkyl pyrimidine deriva-
tives 6 and 7, respectively. On the other hand, alkylation of 4 with 2,3,4,6-tetra-O-acetyl -
-a-D-glucosyl bromide in acetone and in the presence of aqueous potassium hydroxide
afforded the corresponding S-glucosides 8 in good yield (Scheme 2). Attachment of the
glucosyl residues to the sulfur atom rather than to the nitrogen atom was supported by
the value of the chemical shift of the anomeric protons which should other-wise appear
at a lower field. The anomeric proton of b-N-glucosides having an adjacent C=S was re-
ported (15) to appear at a higher chemical shift (d 6.90–7.20 ppm) due to the anisotropic
deshielding effect of the C=S. The structure of 8 was confirmed by elemental analysis and
spectral data. The IR spectrum showed absorption bands at 3192, 2211 and 1718–1667
cm–1 due to the presence of NH, CN and C=O groups, respectively. The 1H NMR spec-
trum showed the anomeric proton of the glucose moiety as a doublet at d 5.70 ppm with
a coupling constant J1'-2' = 9.8 Hz, indicating that H-1’ is trance-dioxal to H-2’. The other
six glucose protons resonated at d 3.75–5.49 ppm and four acetyl groups appeared as
four singlet peaks at d 2.04–2.20 ppm. In addition, its C, H, N analysis data revealed the
molecular formula C33H29ClN4O11S.
When compound 2 was allowed to react with benzaldehyde, it afforded 6-(4-chloro-
-phenylamino)-4-oxo-2-phenyl-1,2,3,4-tetrahydrofuro[3,2-d]pyrimidine-7-carbonitrile (9)
in good yield (Scheme 3). Also, compound 2 reacted with cyclopentanone or cyclohe-
xanone in refluxing acetic acid and sodium acetate to afford the corresponding pyrimi-
dine derivatives 10 and 11, respectively. On the other hand, when compound 2 was trea-
ted with acetic anhydride, it afforded the corresponding furo[3,2-d][1,3]oxazine deriva-
tive 12 (Scheme 3). The 1H NMR spectrum of compound 12, for example, showed a sin-
glet at d 1.30 ppm, which supported the methyl protons and signal at d 2.4 ppm for the
methoxy group, supporting the acetylation of NH group. The MS gave the molecular ion
peak at m/z (%) = 343 (65).
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A very interesting reaction occurred when compound 2 was allowed to react with
carbon disulfide in dry pyridine to produce 1-(4-chlorophenyl)-4-imino-2,6-dithioxo-1,4,
6,7-tetrahydro-pyrimido[5,4-b]furo[5,4-d]-1,3-thiazin-8-one (13) (Scheme 4). The structu-
re of compound 13 was confirmed from its spectral data. On the other hand, when trea-
ted with aliphatic acids, namely chloroacetic acid or chloropropionic acid compound 13
afforded polycyclic fused compounds 14 and 15, respectively. Beside the values in ele-
mental analyses and spectral data, the latter compounds were confirmed chemically via
condensation with benzaldehyde to give the corresponding aryl methylene compounds
16 and 17, respectively (Scheme 4).
Antimicrobial activity
The antimicrobial results as the average diameter of inhibition zones, expressed in
mm are given in Table III. It is evident that all tested compounds display activity against
Bacillus subtilis, Staphylococcus aureus and Escherichia coli while only compounds 6, 9, 11,
17 and 18 were active against Candida albicans as well. Compounds 5, 6, and 8 were the
most active ones against all the listed bacteria. Mean inhibition zones and minimal in-
hibitory concentrations of these compounds ranged from 20 to 30 mm and from 0.17 to
0.68 mg mL–1, respectively. Compounds 6 and 8 also exhibited activity against the fun-
gus C. albicans. All tested compounds showed activity lower than that of the standard
drugs (ciprofloxacin and ketaconazole).
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Bacillus subtilis Staphylococcus aureus Escherichia coli Candida albicans
DMSO(solvent) – – – –
2a 14 21 21 –
3a 13 19 16 –
5a 23 25 30 –
6a 25 25 20 17
8a 20 25 24 14
9a 14 18 19 –
10a 19 24 20 16
16a 16 20 14 16
17a 17 22 21 20
Ciprofloxacinb 23 23 25 –
Ketaconazoleb – – – 23
a 100 mg mL–1
b 50 mg mL–1
Table IV. MIC of the newly synthesized compounds
Compd.
No.
Minimum inhibitory concentration (mg mL–1)
Gram positive bacteria Gram negative bacteria Fungus
Bacillus subtilis Staphylococcus aureus Escherichia coli Candida albicans
5 0.34 0.34 0.17 1.7
6 0.34 0.34 0.68 0.85
8 0.68 0.34 0.34 1.7
10 0.68 0.34 0.68 0.85
17 0.85 0.68 0.68 0.68
Ciprofloxacin
(mg mL–1)
0.12 0.15 0.01 –
Ketaconazole
(mg mL–1)
– – – 0.03
CONCLUSIONS
Screening data of the prepared compounds show promising antibacterial and anti-
fungal activity. Compounds 8, 10 and 16 showed significant antibacterial activity due to
the presence of the sugar moiety and addition of cycloalkane or thiazole to the furano-
pyrimidine ring. Efficacy of compound 6 is probably due to addition of chloroacetone to
the furopyrimidine ring.
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S A @ E T A K
Antimikrobno djelovanje nekih glukopiranozil-pirimidin
karbonitrila i fuzioniranih pirimidinskih sustava
HAYAM H. SAYED, HEBAT-ALLAH S. ABBAS, EMAN M. H. MORSI,
ABD EL-GALIL E. AMR i NAYERA A. M. ABDELWAHAD
3-Amino-5-(4-klorfenilamino)-4-cijanofuran-2-karboksamid (2) upotrebljen je kao
klju~ni spoj za pripravu razli~itih furo-pirimidina 3-9 i spiro-cikloalkan furopirimidina
10 i 11. Fuzionirani heterocikli~ki spojevi 13-17 pripravljeni su tako|er polaze}i iz spoja
2. Sintetizirani spojevi ispitani su na antimikrobno djelovanje.
Klju~ne rije~i: pirimidin, glukopiranozil-pirimidin, oksazin, antimikrobno djelovanje
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